Action Sangamo Therapeutics - SGMO

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

1,05

Prix Achat

0,80

Prix Vente

1,06

Volume échangé

5 252 536

0,9613 Fourchette du Jour 1,06

0,304 Plage de 52 semaines 3,179

Cap du marché

219,079M

Clôture Veille

1,00

Ouverture

1,06

Dernière Transaction

150

1.05

(formt)

Dernière heure de transaction

Volume financier

US$ 5 334 577

VWAP

1,0156

Volume moyen (3 m)

6 580 946

Actions en circulation

208 646 870

Rendement du Dividende

Ratio Cours sur Bénéfices

-0,83

Bénéfice par action (BPA)

-1,24

Chiffre d'affairess

176,23M

Bénéfice net

-257,83M

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemoph... Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies. Show more

Secteur

Biological Pds,ex Diagnstics

Industrie

Biological Pds,ex Diagnstics

Site Web

www.sangamo.com

Siège social

Wilmington, Delaware, USA

Fondé

Sangamo Therapeutics Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker SGMO. Le dernier cours de clôture d'Sangamo Therapeutics était de US$1,00. Au cours de la dernière année, les actions de Sangamo Therapeutics ont été négociées dans une fourchette de prix de US$ 0,304 à US$ 3,179.

Sangamo Therapeutics compte actuellement 208 646 870 actions en circulation. La capitalisation boursière d'Sangamo Therapeutics est de US$208,65 million. Sangamo Therapeutics a un ratio cours/bénéfice (ratio PE) de -0.83.

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the...

Form 4 - Statement of changes in beneficial ownership of securities

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.110443	11.754795079	0.939557	1.05	0.7969	4133692	0.93096148	CS
4	-0.2012	-16.0805626598	1.2512	1.29	0.7969	3691553	1.03960974	CS
12	-0.995	-48.6552567237	2.045	2.84	0.7969	6580946	1.53470652	CS
26	0.31	41.8918918919	0.74	3.179	0.7	6854041	1.64118065	CS
52	0.01	0.961538461538	1.04	3.179	0.304	7382399	1.1443985	CS
156	-4.46	-80.943738657	5.51	6.42	0.2911	3659614	1.55686098	CS
260	-6.65	-86.3636363636	7.7	19.43	0.2911	2827695	3.57369835	CS

SGMO - Frequently Asked Questions (FAQ)

What is the current Sangamo Therapeutics share price?

The current share price of Sangamo Therapeutics is US$ 1,05

How many Sangamo Therapeutics shares are in issue?

Sangamo Therapeutics has 208 646 870 shares in issue

What is the market cap of Sangamo Therapeutics?

The market capitalisation of Sangamo Therapeutics is USD 208,65M

What is the 1 year trading range for Sangamo Therapeutics share price?

Sangamo Therapeutics has traded in the range of US$ 0,304 to US$ 3,179 during the past year

What is the PE ratio of Sangamo Therapeutics?

The price to earnings ratio of Sangamo Therapeutics is -0,83

What is the cash to sales ratio of Sangamo Therapeutics?

The cash to sales ratio of Sangamo Therapeutics is 1,22

What is the reporting currency for Sangamo Therapeutics?

Sangamo Therapeutics reports financial results in USD

What is the latest annual turnover for Sangamo Therapeutics?

The latest annual turnover of Sangamo Therapeutics is USD 176,23M

What is the latest annual profit for Sangamo Therapeutics?

The latest annual profit of Sangamo Therapeutics is USD -257,83M

What is the registered address of Sangamo Therapeutics?

The registered address for Sangamo Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Sangamo Therapeutics website address?

The website address for Sangamo Therapeutics is www.sangamo.com

Which industry sector does Sangamo Therapeutics operate in?

Sangamo Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ABLVAble View Global Inc	US$ 1,73 (137,18%)	5,14M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	482,05M
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	622,67M
DWTXDogwood Therapeutics Inc	US$ 6,63 (49,66%)	25,92M
KZIAKazia Therapeutics Ltd	US$ 1,1899 (40,80%)	4,5M
ALBTAvalon GloboCare Corporation	US$ 6,96 (-36,15%)	577,55k
SCNXScienture Holdings Inc	US$ 1,55 (-35,68%)	1,59M
ACXPAcurx Pharmaceuticals Inc	US$ 0,4572 (-29,88%)	1,18M
RETOReTo Eco Solutions Inc	US$ 5,42 (-27,73%)	108,27k
OCTOEightco Holdings Inc	US$ 1,08 (-27,03%)	336,99k
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	622,67M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	482,05M
NVDANVIDIA Corporation	US$ 112,69 (1,92%)	341,94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 10,675 (-0,70%)	143,04M
ICONIcon Energy Corporation	US$ 0,169898 (17,17%)	142,23M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sangamo Therapeutics Inc (SGMO) Cours

Sangamo Therapeutics Inc (SGMO)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Sangamo Therapeutics Inc

SGMO Dernières nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

SGMO - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités